Joseph Boni

6.6k citations

88 papers · 4.7k indexed · 2 hit papers · h-index 28

Impact in

Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Oncology top 1%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research

Papers in

Genetics 20
- Chronic Lymphocytic Leukemia Research 13
Oncology 46
- CAR-T cell therapy research 22
- HER2/EGFR in Cancer Research 13

Co-authors: Manuel Hidalgo Gary Dukart Janice P. Dutcher Gary R. Hudes Cathie Leister Michael B. Atkins Theodore F. Logan Young Joo Park
Journals: Journal of Clinical Oncology (17 papers)Blood (11 papers)Cancer Chemotherapy and Pharmacology (5 papers)Clinical Cancer Research (4 papers)Annals of Oncology (3 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Joseph Boni

86 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study 2005 · 550 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2005 Journal of Clinical Oncology
2004 Journal of Clinical Oncology

Peers

Countries citing papers authored by Joseph Boni

Since Specialization

Citations

This map shows the geographic impact of Joseph Boni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Boni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Boni more than expected).

Fields of papers citing papers by Joseph Boni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Boni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Boni. The network helps show where Joseph Boni may publish in the future.

Co-authors

The 25 scholars most cited alongside Joseph Boni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joseph Boni Line = papers co-authored together Joseph Boni links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma Cancer Chemotherapy and Pharmacology ·Marie Toukam, Jens Wuerthner, Karin Havenith, Mehdi Hamadani, Paolo F. Caimi, Tim Kopotsha, Hans G. Cruz, Joseph Boni	2022	3
2	Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma Cancer Chemotherapy and Pharmacology ·Marie Toukam, Joseph Boni, Mehdi Hamadani, Paolo F. Caimi, Hans G. Cruz, Jens Wuerthner	2022	3
3	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	2020	122
4	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	2019	77
5	Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma Blood ·Graham P. Collins, Steven M. Horwitz, Andrew Davies, Anand B. Karnad, Felipe Samaniego, Alexander I. Spira, Paul Fields, Tobias Menne, Joseph Boni, Hans G. Cruz, Jay Feingold, Shui He, Jens Wuerthner, Mehdi Hamadani	2018	17
6	Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma Blood ·Mehdi Hamadani, Graham P. Collins, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Paolo Caimi, Tobias Menne, Joseph Boni, Hans G. Cruz, Jay Feingold, Shui He, Jens Wuerthner, Steven M. Horwitz	2018	35
7	Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia Blood ·Aaron D. Goldberg, Martin S. Tallman, Melhem Solh, David Ungar, David A. Rizzieri, Roland B. Walter, Alexander I. Spira, Ki-Young Chung, Wendy Stock, Shui He, Joseph Boni, Ehab Atallah	2017	8
8	Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma Blood ·Brad S. Kahl, Mehdi Hamadani, Paolo F. Caimi, Carmelo Carlo‐Stella, Erin Reid, Jay Feingold, Kirit M. Ardeshna, John Radford, Melhem Solh, Ki-Young Chung, Leonard T. Heffner, Shui He, Joseph Boni, Owen A. O’Connor	2017	6
9	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, Taro Ishibashi, M. Luisa Paccagnella, Joseph Boni, Erik Vandendries, David MacDonald	2016	28
10	Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects Drug Metabolism and Personalized Therapy ·Richat Abbas, Joseph Boni, Daryl Sonnichsen	2015	26
11	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab Journal of Clinical Oncology ·Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, A. Z. S. Rohatiner, Anjali S. Advani, James M. Foran, Georg Heß, Bertrand Coiffier, Myron S. Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang	2013	119
12	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study Journal of Clinical Oncology ·Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James M. Foran, Eva Giné, Christian Gisselbrecht, Nicolas Ketterer, Sunita D. Nasta, A. Z. S. Rohatiner, Ingo G.H. Schmidt‐Wolf, Martin Schüler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad	2010	255
13	Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma Ghent University Academic Bibliography (Ghent University) ·Gregor Verhoef, N. H. Dang, Mitchell R. Smith, F. Offner, Peter Johnson, A. Z. S. Rohatiner, Johnathan Kaufman, Eva Giné, B Coiffier, M. S. Czuczman, James M. Foran, Simon Durrant, Steven Y. Hua, Erik Vandendries, Joseph Boni, Luis Fayad	2010	2
14	mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals Molecular Cancer Therapeutics ·Joseph Boni, Jaime Burns, Bruce A. Hug, Daryl Sonnichsen	2007	4
15	Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450‐Inducing Medications¹ The Journal of Clinical Pharmacology ·Joseph Boni, Cathie Leister, Jaime Burns, Maria Cincotta, Bruce A. Hug, Laurence Moore	2007	38
16	Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Charles Erlichman, Manuel Hidalgo, Joseph Boni, Patrícia Rocha Martins, Susan Quinn, Charles Zacharchuk, Peter Amorusi, Alex A. Adjei, Eric K. Rowinsky	2006	109
17	Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer Clinical Pharmacology & Therapeutics ·Joseph Boni, Cathie Leister, Gregor Bender, Virginia Fitzpatrick, Natalie C. Twine, Jennifer A. Stover, Andrew J. Dorner, Fred Immermann, Michael E. Burczynski	2005	68
18	Five-year study on the injury of the great thoracic vessels after penetrating chest injury. PubMed ·Kiss Ss, Anikó Panna Tóth, Sándor Kollár, Z Nábrádi, Joseph Boni	1999	3
19	alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A. PubMed ·Lee M. Greenberger, Karen I. Collins, Tami Annable, Joseph Boni, María May, F. M. Lai, Gerhard Kramer, R. V. Citeralla, William Hallett, Dennis Powell	1996	8
20	Pyrolysis and Volatilization of Cocaine Journal of Analytical Toxicology ·Billy R. Martin, Louis P. Lue, Joseph Boni	1989	65

About Joseph Boni

Joseph Boni is a scholar working on Genetics, Oncology, Pathology and Forensic Medicine, Pharmacology and Radiology, Nuclear Medicine and Imaging, having authored 88 papers that have together received 4.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (25 papers), CAR-T cell therapy research (22 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), PI3K/AKT/mTOR signaling in cancer (16 papers), Chronic Lymphocytic Leukemia Research (13 papers), HER2/EGFR in Cancer Research (13 papers), Cancer therapeutics and mechanisms (10 papers) and Pharmacogenetics and Drug Metabolism (9 papers). The work is most often cited by research in Genetics (766 citations), Oncology (1.8k citations), Cancer Research (822 citations), Pathology and Forensic Medicine (965 citations) and Pulmonary and Respiratory Medicine (1.4k citations). Joseph Boni has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Manuel Hidalgo, Gary Dukart, Janice P. Dutcher, Gary R. Hudes, Cathie Leister, Michael B. Atkins, Theodore F. Logan, Young Joo Park, Matthew L. Sherman and Walter M. Stadler. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact